
Global Primary Progressive Multiple Sclerosis Market Analysis, Drivers, Restraints, Opportunities, Trends, and Growth Forecast to 2027
-
608
-
Jan 2022
-
153
-
PDF
-
-
Global Primary Progressive Multiple Sclerosis Market Overview
"The Primary Progressive Multiple Sclerosis Market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031."
Multiple sclerosis (MS), also known as disseminated sclerosis, is an inflammatory disease of the nervous system. It is mainly characterized by the disruption of the nerve cells of the spinal cord and the brain of an affected individual, which results in the loss of ability to communicate along with various other physical, mental, and psychiatric problems.
Primary progressive multiple sclerosis (PPMS) is a type of MS in which the neurological functioning steadily deteriorates with no distinct relapses or fixed periods of remission. Only 10% - 15% of the total multiple sclerosis(MS) patients are diagnosed with primary progressive multiple sclerosis (PPMS).
The rate of progression of PPMS may differ from person to person and over time. Signs of temporary improvement may be visible, but the disease progression remains consistent.
High prevalence of neurological disorders and demand for advanced therapeutics for the treatment of primary progressive multiple sclerosis (PPMS) are key drivers driving the growth of the global primary progressive multiple sclerosis market. Increasing awareness among the general population and the availability of affordable medication for treating PPMS are other major factors responsible for the growth of the global primary progressive multiple sclerosis (PPMS) market.
However, inaccurate methods for diagnosis and treatment of primary progressive multiple sclerosis (PPMS), is a major restraint for the growth of the global primary progressive multiple sclerosis (PPMS) market. Awareness among the general population and unavailability of proper treatment in remote areas are some restraining factors for the growth of the primary progressive multiple sclerosis market.
As incidence of primary progressive multiple sclerosis is growing, demand for advanced therapeutics for the treatment of PPMS is at an all-time high. This untapped demand from emerging economies provides an opportunity for growth of the global primary progressive multiple sclerosis(PPMS) market.
North America and Europe are expected to dominate the global primary progressive sclerosis(PPMS) market, owing to high demand of therapeutic drugs and effective treatment of PPMS in these geographies. According to multiple sclerosis portal, 0.5 million people are affected with multiple sclerosis in Europe and 0.4 million people affected population is present in the United States. Asia Pacific is expected to grow at a much faster pace over the forecast period, due to rising awareness among people and growth in emerging economics like India and China
Global Primary Progressive Multiple Sclerosis Market Segmentation:
Global primary progressive multiple sclerosis market segmentation by types of treatment:
- Magnetic Resonance Imaging (MRI) Scans
- Simple electrical stimulation tests
- Lumbar puncture
Global primary progressive multiple sclerosis market segmentation by location of treatment:
- Hospital testing
- Commercial/private hospitals
- Public health hospitals
- Symptomatic diagnostic testing with medications
- Clinics
- Home Treatment
- Managing symptoms
- Rehabilitation
- Healthy living
Global primary progressive multiple sclerosis market segmentation by region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
- Hoffmann-La Roche Ltd.
- Innate Immunotherapeutics Ltd.
- Teva Pharmaceutical Industries
- Roche
- Genzyme Corporation
- Glialogix, Inc.
- Kyorin Pharmaceutical Co., Ltd.
- MedDay SA
- Santhera Pharmaceuticals Holding AG
- AB Science
-
Request for TOC
-
Inquiry Form
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
-
Request for Customization
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!